

## Temixys<sup>™</sup> (lamivudine/tenofovir disoproxil fumarate) – New drug approval

- On November 16, 2018, the <u>FDA approved</u> Celltrion's <u>Temixys (lamivudine/tenofovir disoproxil fumarate)</u>, to be used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg.
- Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are both nucleoside reverse transcriptase inhibitors.
  - A fixed-dose combination of 3TC/TDF is also available as brand Cimduo™.
- The approval of Temixys was based on data from a study comparing 3TC 300 mg + TDF 300 mg + efavirenz (EFV) 600 mg vs. stavudine (d4T) 40 mg + 3TC 300 mg + EFV 600 mg in 600 antiretroviral-naïve adult patients with HIV-1 infection.
  - At week 48, 79% of patients were responders (HIV-1 RNA < 400 copies/mL) in the 3TC/TDF/EFV group vs. 82% in the d4T/3TC/EFV group. At week 144, 68% of patients were responders in the 3TC/TDF/EFV group vs. 62% in the d4T/3TC/EFV group.
- Temixys carries a boxed warning for post-treatment exacerbations of hepatitis B.
- Other warnings and precautions of Temixys include lactic acidosis and severe hepatomegaly with steatosis, risk of hepatic decompensation when used with interferon- and ribavirin-based regimens, pancreatitis, new onset or worsening renal impairment, immune reconstitution syndrome, bone effects, and early virologic failure.
- The most common adverse reactions (> 10%) with Temixys use were headache, pain, depression, diarrhea, and rash.
- The recommended dose of Temixys is one tablet taken orally once daily with or without food.
  - Prior to initiation of Temixys, patients should be tested for hepatitis B virus infection.
  - Serum creatinine, serum phosphorous, estimated creatinine clearance (CrCL), urine glucose, and urine protein should be assessed before initiating Temixys and during therapy in all patients as clinically appropriate.
- Celltrion's launch plans for Temixys are pending. Temixys will be available in a fixed-dose combination tablet containing 300 mg 3TC and 300 mg TDF.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.